Special Article| Volume 49, ISSUE 7, P728-730, July 2017

Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn’s disease?

Published:April 26, 2017DOI:


      Crohn’s disease (CD) is a chronic inflammatory condition of the bowel, characterized by an alternation of remission and relapse phases, leading to a progressive intestinal damage with loss of function. Magnetic resonance enterography has been widely used in the past for the evaluation of fistulizing disease, but its use increased over time, being considered helpful in different moments of disease course. Intravenous injection of Gadolinium-based contrast agents has been demonstrated to be crucial to assess mucosal inflammation, transmural involvement, and extraintestinal disease. Recently, Gadolinium accumulation in human tissues has been increasingly reported, although clinical implications of this event are still unclear. In the present paper, we review the main evidence on the topic, focusing on the potential implications for gastroenterological practice.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Thia K.T.
        • Sandborn W.J.
        • Harmsen W.S.
        • et al.
        Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort.
        Gastroenterology. 2010; 139: 1147-1155
        • Orlando A.
        • Guglielmi F.W.
        • Cottone M.
        • et al.
        Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease.
        Digestive and Liver Disease. 2013; 45: 986-991
        • Gomollón F.
        • Dignass A.
        • Annese V.
        • et al.
        3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management.
        Journal of Crohn’s and Colitis. 2016; 11: 3-25
        • Szurowska E.
        • Wypych J.
        • Izycka-Swieszewska E.
        Perianal fistulas in Crohn’s disease: MRI diagnosis and surgical planning: MRI in fistulazing perianal Crohn’s disease.
        Abdominal Imaging. 2007; 32: 705-718
        • Essary B.
        • Kim J.
        • Anupindi S.
        • et al.
        Pelvic MRI in children with Crohn disease and suspected perianal involvement.
        Pediatric Radiology. 2007; 37: 201-208
        • Panes J.
        • Bouhnik Y.
        • Reinisch W.
        • et al.
        Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.
        Journal of Crohn’s and Colitis. 2013; 7: 556-585
        • Bruining D.H.
        • Loftus Jr., E.V.
        Technology insight: new techniques for imaging the gut in patients with IBD.
        Nature Clinical Practice Gastroenterology & Hepatology. 2008; 5: 154-161
        • Rimola J.
        • Ordás I.
        • Rodriguez S.
        • et al.
        Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity.
        Inflammatory Bowel Diseases. 2011; 17: 1759-1768
        • Pariente B.
        • Mary J.Y.
        • Danese S.
        • et al.
        Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.
        Gastroenterology. 2015; 148: 52-63
        • Fiorino G.
        • Bonifacio C.
        • Allocca M.
        • et al.
        Bowel damage as assessed by the Lémann index is reversible on anti-TNF therapy for Crohn’s disease.
        Journal of Crohn’s and Colitis. 2015; 9: 633-639
        • Bodini G.
        • Giannini E.G.
        • De Maria C.
        • et al.
        Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn’s disease. A study performed using the Lémann index.
        Digestive and Liver Disease. 2017; 49: 175-180
        • Prassopoulos P.
        • Papanikolaou N.
        • Grammatikakis J.
        • et al.
        MR enteroclysis imaging of Crohn disease.
        Radiographics. 2001; 2: 161-172
        • Röttgen R.
        • Grandke T.
        • Grieser C.
        • et al.
        Measurement of MRI enhancement kinetics for evaluation of inflammatory activity in Crohn’s disease.
        Clinical Imaging. 2010; 34: 29-35
        • Sconfienza L.M.
        • Cavallaro F.
        • Colombi V.
        • et al.
        In-vivo axial-strain sonoelastography helps distinguish acutely-inflamed from fibrotic terminal ileum strictures in patients with Crohn's Disease: preliminary results.
        Ultrasound in Medicine & Biology. 2016; 42: 855-863
        • De León-Rodríguez L.M.
        • Martins A.F.
        • Pinho M.C.
        • et al.
        Basic MR relaxation mechanisms and contrast agent design.
        Journal of Magnetic Resonance Imaging. 2015; 42: 545-565
        • Zhou Z.
        • Lu Z.R.
        Gadolinium-based contrast agents for MR cancer imaging.
        Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 2013; 5: 1-18
        • Stojanov D.
        • Aracki-Trenkic A.
        • Benedeto-Stojanov D.
        Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
        Neuroradiology. 2016; 58: 433-441
        • Wiener E.C.
        • Brechbiel M.W.
        • Brothers H.
        • et al.
        Dendrimer-based metal-chelates-a new class of magnetic-resonance-imaging contrast agents.
        Magnetic Resonance in Medicine. 1994; 31: 1-8
        • Bellin M.F.
        • Van der Molen A.J.
        Extracellular gadolinium-based contrast media: an overview.
        European Radiology. 2008; 66: 160-167
        • Todd D.J.
        • Kay J.
        Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity.
        Current Rheumatology Reports. 2008; 10: 195-204
        • Cowper S.E.
        • Robin H.S.
        • Steinberg S.M.
        • et al.
        Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.
        Lancet. 2000; 356: 1000-1001
        • Daram S.R.
        • Cortese C.M.
        • Bastani B.
        Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review.
        American Journal of Kidney Diseases. 2005; 46: 754-759
        • Todd D.J.
        • Kagan A.
        • Chibnik L.B.
        • et al.
        Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure.
        Arthritis & Rheumatology. 2007; 56: 3433-3441
        • Ting W.W.
        • Stone M.S.
        • Madison K.C.
        • et al.
        Nephrogenic fibrosing dermopathy with systemic involvement.
        Archives of Dermatology. 2003; 139: 903-906
        • Thomsen H.S.
        • Morcos S.K.
        • Almen T.
        • et al.
        Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.
        European Radiology. 2013; 23: 307-318
        • Weinmann H.J.
        • Brasch R.C.
        • Press W.R.
        • et al.
        Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent.
        AJR. American Journal of Roentgenology. 1984; 142: 619-624
        • Joffe P.
        • Thomsen H.S.
        • Meusel M.
        Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
        Academic Radiology. 1998; 5: 491-502
        • Gibby W.A.
        • Gibby K.A.
        • Gibby W.A.
        Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy.
        Investigative Radiology. 2004; 39: 138-142
        • Kanda T.
        • Ishii K.
        • Kawaguchi H.
        • et al.
        High signal intensity in the dentate nucleus and globus pallidus on images: relationship with increasing cumulative dose of a gadolinium-based contrast material.
        Radiology. 2014; 270: 834-841
        • Kanda T.
        • Fukusato T.
        • Matsuda M.
        • et al.
        Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy.
        Radiology. 2015; 276: 228-232
        • Ramalho J.
        • Semelka R.C.
        • Alobaidy M.
        • et al.
        Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide.
        European Radiology. 2016; 26: 4080-4088
        • Aime S.
        • Caravan P.
        Biodistribution of gadolinium-based contrast agents, including gadolinium deposition.
        Journal of Magnetic Resonance Imaging. 2009; 30: 1259-1267
        • McDonald R.J.
        • McDonald J.S.
        • Kallmes D.F.
        • et al.
        Intracranial gadolinium deposition after contrast-enhanced MR imaging.
        Radiology. 2015; 275: 772-782
        • Roccatagliata L.
        • Vuolo L.
        • Bonzano L.
        • et al.
        Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype.
        Radiology. 2009; 251: 503-510
        • Frenzel T.
        • Lengsfeld P.
        • Schirmer H.
        • et al.
        Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 °C.
        Investigative Radiology. 2008; 43: 817-828
        • Deepak P.
        • Kolbe A.B.
        • Fidler J.L.
        • et al.
        Update on magnetic resonance imaging and ultrasound evaluation of Crohn’s disease.
        Gastroenterology & Hepatology. 2016; 12: 226-236
        • Doniselli F.M.
        • Albano D.
        • Chianca V.
        • et al.
        Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: what rheumatologists should know.
        Clinical Rheumatology. 2017; 36: 977-980
        • Radbruch A.
        Are some agents less likely to deposit gadolinium in the brain.
        Magnetic Resonance Imaging. 2016; 34: 1351-1354
        • Semelka R.C.
        • Ramalho J.
        • Vakharia A.
        • et al.
        Gadolinium deposition disease: initial description of a disease that has been around for a while.
        Magnetic Resonance Imaging. 2016; 34: 1383-1390
        • Burke L.M.
        • Ramalho M.
        • AlObaidy M.
        • et al.
        Self-reported gadolinium toxicity: a survey of patients with chronic symptoms.
        Magnetic Resonance Imaging. 2016; 34: 1078-1080
      1. European Medicines Agency Pharmacovigilance and Risk Assessment Committee (PRAC) EMA/157486/2017. PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations. Available at: [Accessed 20 March 2017].

        • Conti C.B.
        • Giunta M.
        • Gridavilla D.
        • et al.
        Role of bowel ultrasound in the diagnosis and follow-up of patients with Crohn’s disease.
        Ultrasound in Medicine & Biology. 2017; 43: 725-734
        • Serafin Z.
        • Białecki M.
        • Białecka A.
        • et al.
        Contrast-enhanced ultrasound for detection of Crohn’s disease activity: systematic review and meta-analysis.
        Journal of Crohn’s and Colitis. 2016; 10: 354-362
        • Baumgart D.C.
        • Müller H.P.
        • Grittner U.
        • et al.
        US-based real-time elastography of fibrotic gut tissue in stricturing Crohn disease.
        Radiology. 2015; 275: 889-899
        • Dillman J.R.
        • Stidham R.W.
        • Higgins P.D.
        • et al.
        US elastography-derived shear wave velocity helps distinguish acutely inflamed versus fibrotic intestine in a Crohn disease animal model.
        Radiology. 2013; 267: 757-766
        • Dillman J.R.
        • Stidham R.W.
        • Higgins P.D.
        • et al.
        Ultrasound Shear wave elastography helps discriminate low-grade from high-grade bowel wall fibrosis in ex vivo human intestinal specimens.
        Journal of Ultrasound in Medicine. 2014; 33: 2115-2123
        • Quaia E.
        • Sozzi M.
        • Gennari A.G.
        • et al.
        Impact of gadolinium-based contrast agent in the assessment of Crohn’s disease activity: is contrast agent injection necessary?.
        Journal of Magnetic Resonance Imaging. 2016; 43: 688-697
        • Li X.H.
        • Sun C.H.
        • Mao R.
        • et al.
        Assessment of activity of crohn disease by diffusion-weighted magnetic resonance imaging.
        Medicine (Baltimore). 2015; 94: e1819
        • Neubauer H.
        • Pabst T.
        • Dick A.
        • et al.
        Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRI.
        Pediatric Radiology. 2013; 43: 103-114